Orexo Q3: Aiming above steady-state - Redeye

Redeye maintains its positive view of Orexo after the Q3 report. Although Zubzolv® revenue growth is primarily explained by favorable currency we are encouraged by the positive results from Orexo’s clinical phase I trial with the company’s nasal epinephrine (adrenaline), OX640. We reiterate our base case of SEK42 per share.

Länk till analysen i sin helhet: https://www.redeye.se/research/861492/orexo-q3-aiming-above-steady-state?utm_source=finwire&utm_medium=RSS